Steve Gilman

(Dr. Steven Gilman Ph.D.)

Currently holds positions in SCYNEXIS Inc, Cubist Pharmaceuticals LLC, Momenta Pharmaceuticals Inc, Vericel Corp and Akebia Therapeutics Inc

Positions
Position Company Period
Director SCYNEXIS Inc Feb. 25, 2015 -
Executive Vice President - Research and Development, Chief Scientific Officer Cubist Pharmaceuticals LLC Sept. 7, 2010 -
Independent Director Momenta Pharmaceuticals Inc June 22, 2016 -
Independent Director Vericel Corp Jan. 1, 2017 -
Independent Director Akebia Therapeutics Inc Dec. 12, 2018 -
Chairman of the Board, President, Chief Executive Officer ContraFect Corp Jan. 1, 2017 - April 2, 2019
Independent Director Keryx Biopharmaceuticals Inc March 31, 2016 - Dec. 12, 2018
Chairman of the Board, Chief Executive Officer ContraFect Corp July 21, 2016 - Jan. 1, 2017
Director Vericel Corp Jan. 6, 2015 - Jan. 1, 2017
Chairman of the Board, Interim Chief Executive Officer ContraFect Corp March 21, 2016 - July 21, 2016
Executive Chairman of the Board ContraFect Corp May 20, 2015 - March 21, 2016
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Total value Details
2022-06-07 2022-06-03
PS Planned sale
4,567 -9.5%
0.36
1,653 USD 		4,567 -9.5% 0.36 1,653 USD
2022-05-02 2022-04-29
US Vericel Corp (VCEL)
PS Planned sale
900 -14.8%
30.94
27,846 USD 		900 -14.8% 30.94 27,846 USD
2021-12-01 2021-11-29
US Vericel Corp (VCEL)
PS Planned sale
5,000 -58.8%
39.17
195,855 USD 		5,000 -58.8% 39.17 195,855 USD
2021-10-28 2021-10-27
US Vericel Corp (VCEL)
PS Planned sale
5,000 -58.8%
50.57
252,870 USD 		5,000 -58.8% 50.57 252,870 USD
2021-10-01 2021-09-30
US Vericel Corp (VCEL)
PS Planned sale
5,000 -58.8%
48.85
244,255 USD 		5,000 -58.8% 48.85 244,255 USD
2021-06-09 2021-06-07
PS Planned sale
4,567 -8.7%
3.32
15,163 USD 		4,567 -8.7% 3.32 15,163 USD
2020-12-23 2020-12-21
US SCYNEXIS Inc (SCYX)
B Purchase
4,000 +inf%
6.25
25,000 USD 		4,000 +inf% 6.25 25,000 USD
2020-08-07 2020-08-05
PS Planned sale
13,000 -62.5%
32.75
425,750 USD 		13,000 -62.5% 32.75 425,750 USD
2020-07-30 2020-07-29
PS Planned sale
10,000 -56.2%
29.70
297,000 USD 		10,000 -56.2% 29.70 297,000 USD
2020-07-23 2020-07-22
PS Planned sale
10,000 -56.2%
33.23
332,300 USD 		10,000 -56.2% 33.23 332,300 USD
2020-06-09 2020-06-08
PS Planned sale
4,567 -10.5%
12.08
55,169 USD 		4,567 -10.5% 12.08 55,169 USD
2019-05-03 2019-05-01
US Vericel Corp (VCEL)
PS Planned sale
7,500 -100.0%
16.81
126,095 USD 		7,500 -100.0% 16.81 126,095 USD
2019-03-04 2019-02-28
US Vericel Corp (VCEL)
PS Planned sale
7,500 -100.0%
18.02
135,129 USD 		7,500 -100.0% 18.02 135,129 USD